| Similar Articles |
|---|
 |
The Motley Fool
January 2, 2004
Alyce Lomax |
A Bitter Pill for Amerisource Veterans ditch Amerisource for rival; investors punish the entire pharmaceutical distribution industry.   |
The Motley Fool
January 26, 2004
Alyce Lomax |
Amerisource's Fightin' Words Wholesale drug distributor AmerisourceBergen's first-quarter profits rise, but will a fight with veterans end peacefully? |
The Motley Fool
April 7, 2011
Brandon Glenn |
"Generic Wave" to Drive Cardinal Health's Profitability in Coming Years The generic wave could mean big money for Cardinal and top competitors. |
The Motley Fool
January 7, 2010
Brian Orelli |
Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered. |
The Motley Fool
July 1, 2004
W.D. Crotty |
Drug Wholesalers Taking a Beating A sharp drop at drug wholesaler Cardinal Health provides a unique buying opportunity. |
The Motley Fool
October 8, 2007
Billy Fisher |
McKesson Expands Its Empire A new acquisition strengthens the company's presence in the cancer drug market. Investors, take note. |
The Motley Fool
November 9, 2005
W.D. Crotty |
McKesson Fattens Its Margins The pharma distributor turns in an outstanding second quarter. Because McKesson is a broadly based supplier, it avoids the roller-coaster impact that specific drug successes and failures have on drug-developer stocks. |
The Motley Fool
May 6, 2008
Steven Renaldi |
McKesson Garners Generic Growth New products offer the generic-drug distributor profit potential in a competitive industry. |
The Motley Fool
December 10, 2004
Brian Gorman |
Cardinal Picks a Lilly Cardinal Health's deal with Lilly suggests the new fee-for-service model is gaining traction. |
The Motley Fool
July 28, 2004
Brian Gorman |
Cardinal Watching Cardinal Health continues to be pummeled, but wait patiently, because a buying opportunity could emerge. |
The Motley Fool
May 6, 2005
W.D. Crotty |
McKesson's New Pep Pill The drug wholesaler reports strong fourth-quarter results as it moves to a fee-for-service model. |
The Motley Fool
January 30, 2006
Brian Gorman |
Cardinal Inches Higher The distribution is looking healthier, but Cardinal Health still has work to do. Investors, take note. |
The Motley Fool
March 30, 2011
Sean Williams |
China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps. |
The Motley Fool
June 13, 2006
Ryan Fuhrmann |
Cardinal Looks to Deliver Cardinal Health has been through a tumultuous couple of years but appears to have weathered company-specific and industry storms. If the drug distributor can meet its long-term goals, then its stock should represent a long-term solid investment. |
The Motley Fool
February 1, 2006
Rich Duprey |
Candela Is Finally White Hot The aesthetic laser maker finally produces the white-hot sales growth it promised -- two years ago. In midday trading, the stock soared 30%. |
BusinessWeek
August 30, 2004
Gene G. Marcial |
PSS Is Really Delivering The Goods When David Smith took the CEO job at PSS World Medical in 2000, sales stood at $160 million. They've since rocketed to $1.35 billion. No wonder industry giants are eyeballing the company: They hope Smith will sell. |
The Motley Fool
January 8, 2010
Brian Orelli |
Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands. |
The Motley Fool
January 21, 2005
Rich Duprey |
Cardinal Back in the Nest Drug distributor and Japanese pharma Eisai come to agreement after all. |
The Motley Fool
December 3, 2010
Brian Orelli |
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
May 20, 2010
Brian Orelli |
FDA Transparency! A Big Win for Investors The Food and Drug Administration has possibly just made things easier for investors. Let's just hope drug companies don't shoot it down. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
May 20, 2004
Tom Taulli |
Cardinal Rules of M&A Cardinal Health is upbeat on its latest acquisition, but needs bigger deals to push growth. |
The Motley Fool
December 21, 2006
Brian Lawler |
Dueling Fools: Merck Bull Rebuttal Plenty of cash. Big pipeline. Not to worry. The future can't be predicted, but Merck's history shows its ability to weather even the toughest pharmaceutical-development environments. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
Chemistry World
July 16, 2010
Matt Wilkinson |
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. |
The Motley Fool
September 30, 2004
W. D. Crotty |
Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
BusinessWeek
August 7, 2006
Arlene Weintraub |
McKesson's Booster Shot McKesson Corp. holds the unenviable distinction of being one of the world's biggest yet least profitable companies. The problem: huge sales, tiny profits. High-margin tech products could help. |
The Motley Fool
October 28, 2004
Brian Gorman |
Cardinal's Good News: No News The drug wholesaler took a major step toward rehabilitating itself with the release of its 10-K. |
The Motley Fool
January 26, 2007
Billy Fisher |
A Clean Bill of Health at Cardinal Good results and a key divestiture have this health care company rolling. Investors, take note. |
The Motley Fool
September 7, 2007
Billy Fisher |
Epic Vioxx Victory for Merck Merck scores a major victory in its Vioxx saga in the courtroom as New Jersey's Supreme Court rules against the possibility of a national class action Vioxx lawsuit. Shares react positively. |
The Motley Fool
August 3, 2006
Ryan Fuhrmann |
Cardinal Distributes the Goods The drug wholesaler and distributor has to regain investor confidence and rebuild a track record in a changed industry. So far, so good for 2006. Let's see if any further information can be found once Cardinal submits its 10-K filing to the SEC. |
The Motley Fool
October 28, 2011
Anders Bylund |
Computer Programs & Systems' Shares Got Crushed: What You Need to Know Is this meaningful? Or just another movement for Computer Programs & Systems? |
